OphthaliX Inc. Release: Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra Ocular Pressure and for the Treatment of Glaucoma
5/13/2013 6:32:51 AM
More...
|
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
3/18/2013 9:41:26 AM
More...
|
Dr. Gil Ben-Menachem Appointed Chief Executive Officer of OphthaliX Inc.
12/13/2012 6:41:56 AM
More...
|
OphthaliX Inc. Reports First Quarter 2012 Financial Results
5/16/2012 11:53:28 AM
More...
|
OphthaliX Inc. Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis
4/10/2012 8:41:00 AM
More...
|